The purpose of the present protocol is to develop an in vitro means by which human bone marrow can be cleared of metastatic foci of carcinoma. Preliminary in vitro experiments performed with CELLMAXtm hollow fiber cell culture systems demonstrated that 1) normal human marrow can be grown to produce pluripotent cells yielding all hematopoetic cell types and 2) human T lymphocytes can be expanded to massive numbers for clinical therapy. Activated T cells destroy neoplastic cells both in vivo and in vitro. The present program proposes to culture aliquots of bone marrow from ten patients, each containing metastatic neuroblastoma, breast or prostate carcinoma. These marrows will be maintained within continuously perfused hollow fiber bioreactors for 3 weeks during which time, the endogenous T cells will be activated and expanded by addition of rIL-2. Cells will then be harvested from the extra-fiber space and the numbers of both malignant cells and colony-forming bone marrow stem cells determined. Phenotypic and in vitro cytotoxicity profiles will also be determined. Successful depletion of malignant cells with concomitant maintenance of the colony-forming cells within harvested marrow could enable patients having such metastic malignancies to be treated with marrow-destroying doses of chemotherapy and radiation therapy and then be rescued by re-infusion and engraftment of their own marrow.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA054694-01
Application #
3492843
Study Section
Special Emphasis Panel (SSS (B3))
Project Start
1991-04-01
Project End
1992-03-31
Budget Start
1991-04-01
Budget End
1992-03-31
Support Year
1
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Cellco, Inc.
Department
Type
DUNS #
City
Germantown
State
MD
Country
United States
Zip Code
20874